Jasper Therapeutics, Inc. Stock

Equities

JSPR

US4718712023

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-05-17 EDT 5-day change 1st Jan Change
23.02 USD +0.77% Intraday chart for Jasper Therapeutics, Inc. +7.92% +191.76%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * 5.5M 7.5M Capitalization 347M 473M
Net income 2024 * -67M -91.34M Net income 2025 * -77M -105M EV / Sales 2024 * -
Net cash position 2024 * 217M 296M Net cash position 2025 * - 0 EV / Sales 2025 * 63.1 x
P/E ratio 2024 *
-4.96 x
P/E ratio 2025 *
-5.86 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.39%
More Fundamentals * Assessed data
Dynamic Chart
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 MT
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65 MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating MT
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise MT
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023 CI
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment MT
More news

Latest transcript on Jasper Therapeutics, Inc.

1 day+0.77%
1 week+7.92%
Current month-3.56%
1 month+6.62%
3 months+21.54%
6 months+265.98%
Current year+191.76%
More quotes
1 week
20.60
Extreme 20.6
23.70
1 month
20.15
Extreme 20.15
26.18
Current year
6.41
Extreme 6.41
31.01
1 year
4.00
Extreme 4
31.01
3 years
3.86
Extreme 3.862
188.80
5 years
3.86
Extreme 3.862
188.80
10 years
3.86
Extreme 3.862
188.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 22-03-14
Director of Finance/CFO 52 23-09-21
Chief Tech/Sci/R&D Officer - 19-12-31
Members of the board TitleAgeSince
Chief Executive Officer 62 22-03-14
Chairman 72 10-31
Director/Board Member 56 21-09-23
More insiders
Date Price Change Volume
24-05-17 23.02 +0.77% 65,738
24-05-16 22.84 +5.76% 77,712
24-05-15 21.6 +3.25% 101,371
24-05-14 20.92 +0.77% 39,212
24-05-13 20.76 -2.67% 35,493

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm

More quotes
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
23.02 USD
Average target price
64.17 USD
Spread / Average Target
+178.74%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW